VRG-145 / VRG Therap - LARVOL DELTA

Synergistic antimigraine effects of combined vascular and neural targeting with lisinopril and memantine: Preclinical support for clinical translation (AHS 2026) - "Background: Current standard migraine prophylaxis includes established generics (topiramate, propranolol, amitriptyline) and newer CGRP-targeting therapies, including gepants, one CGRP-receptor antibody, and several ligand-directed antibodies... Randomized controlled trials show that lisinopril and memantine are individually effective migraine preventives, with efficacy comparable to current therapies, producing placebo-corrected reductions of 1.4 and ≥3 monthly migraine days, respectively. Their 1:1 combination (VRG-145) demonstrated robust synergy in two models of chronic trigeminal sensitization and a markedly improved therapeutic index. These findings support clinical translation of VRG-145 at sub- or low-therapeutic component doses, with potential for enhanced efficacy, improved tolerability, and benefit in patients insufficiently responsive to existing preventives."

Preclinical • CNS Disorders • Migraine • Pain

Novamigra Therapeutics Secures ~€3 Million Funding to Advance First-in-Human Study of Migraine Prophylaxis Asset VRG-145 (Firstwordpharma Press Release) - "The proceeds will support the completion of CMC (Chemistry, Manufacturing, and Controls) development, as well as the execution of the company’s first-in-human pharmacokinetic (PK) and safety Phase 1 study....Based on regulatory guidance, Novamigra has finalized the design of its first-in-human Phase 1 study, a 36 healthy volunteer trial designed to assess the pharmacokinetics and safety of VRG-145."

Financing • New P1 trial • Migraine